Astrazeneca finally calls on the EMEA to obtain a marketing authorisation for its vaccine

  •   12/01/2021 - 14h46
  •   HARMANT Adeline

It was the European Medicines Agency that announced this morning what seems to be good news for the fight against Covid-19, since it has received a marketing application from the Astrazeneca laboratory for its vaccine. This news comes just a few days after Sanofi announced that its own vaccine would not be available before the end of 2021.

76.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. Trade CFDs with Plus500
Astrazeneca finally calls on the EMEA to obtain a marketing authorisation for its vaccine
Image copyright: Gwan Kho - Flickr

The decision is expected on January 29:

The European Medicines Agency announced in a press release this morning that it has received an emergency marketing application for the vaccine developed by AstraZeneca in collaboration with Oxford University. This vaccine, which of course aims to stop the coronavirus pandemic in the world, would therefore be the second to be studied by the EMA after the Pfizer/BioNTech vaccine. The agency has stated that it is likely to give its final opinion on the study as early as January 29, in just two weeks' time.

This decision should thus prove to be a rapid one for the upcoming conditional marketing authorization of this vaccine against the new coronavirus.

It should be recalled that the European Medicines Agency had already given its green light on 21 December for the marketing of the vaccine developed by the American firm Pfizer in collaboration with the biotech company BioNTech. On January 6, the vaccine developed by the American biotech company Moderna received the same approval. As for Astraeneca's vaccine, it should be noted that it has already obtained marketing authorization in the United Kingdom. The EMA, which was waiting to finally receive the scientific data that would make it possible to assess the potential use of this vaccine in Europe, will therefore carry out an accelerated examination of the vaccine and will make its decision very quickly if the data are sufficiently complete and convincing.

 

A long-awaited vaccine after the delays by Sanofi :

The decision to fast-track the validation of the AstraZeneca vaccine was taken at a time when the French group was in the process of preparing a new vaccine for the European market.the decision to fast-track the validation of AstraZeneca's vaccine was made even though the French group Sanofi, which is also working on a similar vaccine, announced a few days ago that the vaccine would not be ready before the end of 2021.

Indeed, only clinical trials on animals have so far been carried out and the calendar established by the group shows that the latter has not really grasped the current health emergency by treating this development almost as quickly as for an ordinary vaccine. Thus, after Pfizer and Moderna, it is Astrazeneca that will take a share of this highly coveted market with no doubt many orders to come in the weeks following its approval.

The European Union, like the European Medicines Agency, is currently under pressure to approve new vaccines against the virus that has caused the outbreak of the pandemic.this virus has already caused the death of more than 620,000 people across the European continent and continues to claim victims at the beginning of the third wave.